Clinical Trials Logo

Clinical Trial Summary

The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.


Clinical Trial Description

Urinary tract infection (UTI) is the most common outpatient infection world-wide, and for people with spinal cord injury (SCI) and neurogenic bladder (NB), it is the most common infection, secondary condition, cause for emergency room visits, and infectious cause of hospitalization. Despite its prevalence, attempts to ameliorate UTI among people with SCI are stymied by long-standing diagnostic challenges which arise from evidence gaps around "gold standard" diagnostic tests (urinalysis and urine culture) that have lower sensitivity and specificity for UTI in this population. A high prevalence of chronic inflammation leading to persistence of white blood cells (WBC) in the urine confounds the utility of WBC count, pyuria, and leukocyte esterase as biomarkers for UTI; nitrites in urine indicate the presence of only specific (but not all) organisms, many of which are present to a greater extent in the urine of people with SCI; and people with SCI have a high prevalence of asymptomatic bacteriuria. These physiologic changes render the gold standard diagnostic tests less useful for identifying UTI in persons with SCI. SA1. Estimate healthy, asymptomatic state variability of urine NGAL (uNGAL), white blood cells (uWBC), nitrite, cultivable bacteria, and the urinary microbiome. SA2. Estimate the effect of intravesical LGG dose on urinary symptoms (primary outcome), uNGAL, uWBC, nitrites, cultivable bacteria, and the urine microbiome (secondary outcomes). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04323735
Study type Interventional
Source Medstar Health Research Institute
Contact Amanda K Rounds, PhD
Phone 202-877-1591
Email Amanda.K.Rounds@medstar.net
Status Recruiting
Phase Phase 2
Start date January 10, 2020
Completion date September 2025

See also
  Status Clinical Trial Phase
Recruiting NCT02978638 - Electrical Stimulation for Continence After Spinal Cord Injury N/A
Enrolling by invitation NCT06429631 - The Effect of CIC Education on QOL and Compliance With Mobile Application in Individuals With Spinal Cord Injury. N/A
Completed NCT03573726 - Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life N/A
Recruiting NCT06059066 - Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction N/A
Completed NCT01429090 - Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Phase 1
Recruiting NCT05587101 - Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
Terminated NCT03843073 - Connected Catheter- Safety and Effectiveness Study N/A
Terminated NCT04059159 - Connected Catheter - Safety and Effectiveness Study N/A
Completed NCT05861024 - Urinary Calculi After Bladder Augmentation in Children
Completed NCT05858840 - Urinary Artificial Sphincter in Children
Completed NCT04074616 - Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation N/A
Completed NCT05683938 - GentleCathâ„¢ Air Intermittent Catheter Smartwatch Real Life Pilot Study
Completed NCT04543552 - A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
Active, not recruiting NCT06247033 - Efficacies of Different Managements in Patients With Overactive Bladder With Stroke N/A
Withdrawn NCT01305681 - Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Phase 1/Phase 2
Recruiting NCT04248322 - Qualitative Assessment of the Impact of TTNS on QOL and Participation
Recruiting NCT05301335 - Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study N/A
Recruiting NCT04924569 - Continence Care Registry
Completed NCT01716624 - Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Phase 3
Completed NCT01297647 - Incidence of Urinary Tract Infection After Urodynamic Investigation N/A